Lacking of estradiol reduces insulin exocytosis from pancreatic β-cells and increases hepatic insulin degradation

• Published in: Steroids Vol. 114; pp. 16 - 24
• Main Authors: Santos, Roberta S., Batista, Thiago M., Camargo, Rafael L., Morato, Priscila N., Borck, Patrícia C., Leite, Nayara C., Kurauti, Mirian A., Wanschel, Amarylis C.B.A., Nadal, Ángel, Clegg, Deborah J., Carneiro, Everardo M.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01-10-2016
• Subjects: Animals; Estradiol; Estradiol - blood; Estradiol - therapeutic use; Exocytosis - drug effects; Female; Glucose Intolerance - blood; Glucose Intolerance - drug therapy; Glucose Intolerance - metabolism; IDE; Insulin - blood; Insulin - metabolism; Insulin degradation; Insulin Resistance; Insulin secretion; Insulin-Secreting Cells - drug effects; Insulin-Secreting Cells - metabolism; Liver - drug effects; Liver - metabolism; Mice; Mice, Inbred C57BL; Ovariectomy; SNARE proteins; SNARE Proteins - metabolism; IDE; Insulin degradation; Estradiol; SNARE proteins; Insulin secretion
• ISSN: 0039-128X; 1878-5867
• DOI: 10.1016/j.steroids.2016.05.002

[Display omitted]
•Lack of endogenous estrogens lead to a reduction in pancreatic β-cell exocytosis of insulin.•Lack of endogenous estrogens lead to increased hepatic insulin clearance.•Estrogens regulate protein expression of ERβ, Synt-1A and Snap-25 in the pancreas.•IDE and ERα protein expression are regulated by estrogens in the liver.
Low levels of plasma estrogens are associated with weight-gain, android fat distribution, and a high prevalence of obesity-related comorbidities such as glucose intolerance and type II diabetes. The mechanisms underlying the association between low levels of estrogens and impaired glucose homeostasis are not completely understood. To begin to test this, we used three-month-old female C57BL/6J mice that either underwent ovariectomy (OVX) or received a sham surgery (Sham), and we characterized glucose homeostasis. In a subsequent series of experiments, OVX mice received estradiol treatment (OVX+E2) or vehicle (OVX) for 6 consecutive days. As has been previously reported, lack of ovarian hormones resulted in dysregulated glucose homeostasis. To begin to explore the mechanisms by which this occurs, we characterized the impact of estrogens on insulin secretion and degradation in these mice. Insulin secretion and plasma insulin levels were lower in OVX mice. OVX mice had lower levels of pancreatic Syntaxin 1-A (Synt-1A) protein, which is involved in insulin extrusion from the pancreas. In the liver, OVX mice had higher levels of insulin-degrading enzyme (IDE) and this was associated with higher insulin clearance. Estradiol treatment improved glucose intolerance in OVX mice and restored insulin secretion, as well as normalized the protein content of pancreatic Synt-1A. The addition of estrogens to OVX mice reduced IDE protein to that of Sham mice. Our data suggest loss of ovarian estradiol following OVX led to impaired glucose homeostasis due to pancreatic β-cell dysfunction in the exocytosis of insulin, and upregulation of hepatic IDE protein content resulting in lower insulinemia, which was normalized by estradiol replacement.